ChromaDex to Showcase Premier Innovation and Brand-Elevating Science at Engredea 2017
February 21 2017 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health,
wellness and nutritional ingredients that creates science-based
solutions to dietary supplement, food and beverage, skin care,
sports nutrition, and pharmaceutical products, announced today it
is bringing some of its top industry-advancing health and wellness
products and services to booth #868 at Engredea 2017, taking place
March 9-12 in Anaheim, CA.
ChromaDex is confident that this year’s Engredea attendees will
like what they see and hear at booth #868. In addition to
showcasing exciting ingredient demonstrations, ChromaDex standards
and services experts will be available to discuss how they can help
assure your products are delivering on their brand
promise.
Game-changing reasons to stop by booth #868
- The expanding interest in NIAGEN® (NR). “There
is growing mainstream media interest in NR (nicotinamide riboside),
especially in its ability to support cellular energy production and
activate longevity promoting proteins,” comments Will Black, vice
president of sales and marketing, ChromaDex. “On the heels of the
publication of our first human clinical trial in Nature
Communications, we’re full-scale into human clinical studies and
anticipate additional outcomes this year. Given that NIAGEN® has
both NDI and GRAS status, we are excited to showcase how
effectively it can be formulated into delivery systems and
applications other than capsules, giving consumers great-tasting,
new ways to give their body a boost of NAD+.” See a live
demonstration of NIAGEN® power caps into water. “Our powdered
delivery system tastes great, and is an ideal alternative for
people who can’t take capsules.”
- Discover why pTeroPure® is the new
resveratrol. It’s a 99% pure, nature identical
trans-pterostilbene with antioxidant properties delivering benefits
in the areas of heart health, and support of healthy cellular
function products as a stand-alone ingredient or as an add on to an
existing formula. Frank Jaksch, Jr., CEO and co-founder of
ChromaDex explains, “pTeroPure® molecules have a higher affinity
for fats than resveratrol’s, so it has an improved ability to get
absorbed into cells. In fact, pTeroPure® has been shown to have 80%
bioavailability compared with 20% for resveratrol. Studies are also
showing that pTeroPure® may be superior to resveratrol in
supporting healthy aging. pTeroPure®, but not resveratrol, showed
lower markers of cellular stress and inflammation.”
- Delivering on promise ChromaDex’s analytical
experts will be on hand to talk with attendees about how to ensure
they are in compliance with FDA requirements, verifying that their
brands are delivering on promise. “ChromaDex has a long history of
partnering with customers to confirm identity which protects their
business and their product quality,” comments Jaksch. “Building
trust with consumers is critical. Our customers have high standards
in all areas, including sourcing and testing.”
What’s in your product and how can you be sure it is delivering
on promise? With today’s stringent focus on ingredient quality and
efficacy, ChromaDex provides a comprehensive suite of analytical
services such as contaminant testing, the ComplyID™ raw material
testing program, and finished product testing. It is an
industry-leading provider of phytochemical reference standards,
botanical reference materials, and research grade materials for the
natural products industry. To learn more about working with
ChromaDex, visit www.ChromaDex.com.
About ChromaDex:ChromaDex
leverages its complementary business units to discover, acquire,
develop and commercialize patented and proprietary ingredient
technologies that address the dietary supplement, food, beverage,
skin care and pharmaceutical markets. In addition to our ingredient
technologies unit, we also have business units focused on natural
product fine chemicals (known as "phytochemicals"), chemistry and
analytical testing services, and product regulatory and safety
consulting (known as Spherix Consulting). As a result of our
relationships with leading universities and research institutions,
we are able to discover and license early stage, IP-backed
ingredient technologies. We then utilize our in-house chemistry,
regulatory and safety consulting business units to develop
commercially viable ingredients. Our ingredient portfolio is backed
with clinical and scientific research, as well as extensive IP
protection. Our portfolio of patented ingredient technologies
includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene;
PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a
spirulina extract; and AnthOrigin™, anthocyanins derived from a
domestically-produced, water-extracted purple corn. To learn more
about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related ingredient claims. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
January 2, 2016, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
Statements in this press release have not been evaluated by the
Food and Drug Administration. These products are not intended to
diagnose, treat, cure or prevent any disease.
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024